Implanet SA (FR:ALIMP)
:ALIMP
Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.08 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)332.66K
Market Cap
€27.15M
Enterprise Value€30.07M
Total Cash (Recent Filing)€3.01M
Total Debt (Recent Filing)€5.92M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume485,065
30 Day Avg. Volume332,657
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin ImprovementRevenue rose from €7.45M (2023) to €12.47M (2025) while gross margin expanded to ~55%, indicating strengthening product adoption and/or pricing/mix improvements. Sustained top-line growth plus higher gross margins materially improve the structural path toward operating leverage and eventual profitability if maintained.
Improving Cash Flow TrendOperating cash flow remains negative but improved markedly in 2025 versus 2024, signalling operational progress and tighter working-capital management. A continued trend of cash-flow recovery reduces dependence on external financing and supports sustainable investment in commercialization over the medium term.
Specialized Spine/Orthopedic Product ModelImplanet's focused product portfolio (spine and orthopedic implant systems plus instruments) creates platform stickiness and recurring consumable demand from repeat procedures. This clinical specialization supports durable customer relationships with hospitals and surgeons, improving revenue visibility as adoption grows.
Bears Say
High Leverage And Thin EquityThe capital structure shows very elevated leverage with minimal equity cushion, leaving the company exposed if operating losses persist. High debt amplifies refinancing and interest risks, constraining strategic flexibility and raising solvency concerns until sustained profitability restores equity.
Sustained Negative Cash GenerationPersistent negative operating and free cash flow means ongoing reliance on external funding to support operations and growth. Even with improvement, continued cash burn complicates scaling, increases dilution/refinancing risk, and limits the company's ability to invest in longer-term commercial initiatives without secured capital.
Material Ongoing LossesSignificant negative net margins reflect that cost structure and operating leverage have not yet absorbed growth. Continued material losses erode limited equity, undermine financial resilience, and make access to capital more difficult, jeopardizing the firm's ability to fund commercialization and R&D over the medium term.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.08 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €27.15M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 112 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.162%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet SA (ALIMP) is a French medical technology company specializing in the development and commercialization of innovative implants and associated surgical instruments for orthopedic and spinal surgery. The company focuses on providing advanced solutions to enhance patient outcomes and improve surgical efficiency, with a product portfolio that includes vertebral fixation systems and orthopedic implants tailored for various surgical applications.
Technical Analysis
Theraclion SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Euromedis Groupe SA
―
Median Technologies
―